Understand the role of acquired mutations in resistance to endocrine ... continue to evaluate therapeutics for germline and somatic pathogenic variants. Genomic Signatures in Early-stage ER+ Breast ...

BRCAness refers to tumors that mimic BRCA1/2 mutation behavior, making them vulnerable to DNA-damaging treatments like PARP ...

Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline BRCA-associated breast cancer (SWOG S1416). Number of patients and ...

Former EastEnders star has revealed that she has undergone a double mastectomy, following a gene test which confirmed she ...

Doctors examine a tumor in several different ways to determine whether a cancer is aggressive – and what kinds of treatments, ...

Doctors examine a tumor in several different ways to determine whether a cancer is aggressive – and what kinds of treatments, ...

Genetic testing for hereditary cancer unexpectedly uncovers a case of myelodysplastic syndrome (MDS), highlighting the need ...

This trial evaluated the efficacy and safety of Johnson & Johnson’s (J&J) Akeega, which includes Zejula (niraparib), a highly ...

Supplemental Health Care (SHC) released its 2025 Impact Report, highlighting the organization's ongoing dedication to enhancing its impact on behavioral health, education, and healthcare across the ...

There were 22 men with progressive mCRPC enrolled, the median age at enrollment was 66 years (range 52-80), the median PSA at original diagnosis was 82 ng/mL (range 5-3,648), 55% had a Gleason score 9 ...

Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, today announced promising results from its ...